| Sep 10 |
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
|
| Sep 10 |
Biggest stock movers today: ORCL, RBRK, VRDN, and more
|
| Sep 10 |
Viridian posts initial late-stage trial data for lead asset
|
| Sep 10 |
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
|
| Sep 9 |
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
|
| Sep 5 |
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 30 |
Viridian Therapeutics: Key Inflection Points Ahead
|
| Aug 9 |
Viridian Therapeutics reports Q2 results
|
| Aug 8 |
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
|
| Jul 30 |
Top 3 Health Care Stocks You May Want To Dump This Quarter
|
